Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Yang, Zhongyi ^a   Sun, Yifei ^a   Xue, Jing ^a   Yao, Zhifeng ^a   Xu, Junyan ^a   Cheng, Jingyi ^a   Shi, Wei ^a   Zhu, Beiling ^a   Zhang, Yongping ^a   Zhang, Yingjian ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; TRACER; UNCLASSIFIED DRUG; ESTRADIOL; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RESPONSE; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PET SCANNER; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; FEMALE; FLUORINE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886936965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078192     Document Type: Article

References (34)

1. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493. PubMed: 9215816.
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685. PubMed: 9704717.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ, (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827.
4. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B, (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102. PubMed: 11773300.
5. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, et al. (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027. doi:10.1200/JCO.2005.04.1665. PubMed: 16606972.
6. Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ, (2011) Positron emission tomography and neoadjuvant therapy of breast cancer. J Natl Cancer Inst Monogr(2011): pp. 111-115. PubMed: 22043055.
7. Colleoni M, Montagna E, (2012) Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol 23 (Suppl 10):: x243-x248. PubMed: 22987970.
8. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D, (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.Ann Oncol 21: 1254-1261. doi:10.1093/annonc/mdp427. PubMed: 19858088.
9. Edge SB, Compton CC, (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474. doi:10.1245/s10434-010-0985-4. PubMed: 20180029.
10. Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ, Yonekura Y, et al. (2006) Automatic synthesis of 16 alpha-[(18)F]fluoro-17beta-estradiol using a cassette-type [(18)F]fluorodeoxyglucose synthesizer. Nucl Med Biol 33: 281-286. doi:10.1016/j.nucmedbio.2005.11.002. PubMed: 16546684.
11. Zhang YP, Zhang YJ, Wang MW, Liu HX, Yang ZY, et al. (2011) Fully automated synthesis of 16α [18F]fluoro-17β-estrogen using Explora GN/LC dual module. Chin J Nucl Med 31: 196-200.
12. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, et al. (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306. PubMed: 7874340.
13. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, et al. (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24: 5366-5372. doi:10.1200/JCO.2006.05.7406. PubMed: 17088570.
14. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T, (2011) Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 18: 3160-3163. doi:10.1245/s10434-011-1919-5. PubMed: 21947594.
15. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, et al. (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37: 931-938. PubMed: 8683314.
16. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, et al. (2000) Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676-1688. PubMed: 10764428.
17. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, et al. (2002) Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 38: 375-379. doi:10.1016/S0959-8049(01)00379-3. PubMed: 11818202.
18. Kim SJ, Kim SK, Lee ES, Ro J, Kang Sh, (2004) Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15: 1352-1357. doi:10.1093/annonc/mdh345. PubMed: 15319241.
19. Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, et al. (2008) Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 19: 1573-1577. doi:10.1093/annonc/mdn185. PubMed: 18552360.
20. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, et al. (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14: 6580-6589. doi:10.1158/1078-0432.CCR-07-4310. PubMed: 18927299.
21. Pickles MD, Gibbs P, Lowry M, Turnbull LW, (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24: 843-847. doi:10.1016/j.mri.2005.11.005. PubMed: 16916701.
22. Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, et al. (2010) Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 23: 233-241. PubMed: 20175134.
23. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, et al. (2009) Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. A Am J Surg 198: 520-525. PubMed: 19800460.
24. Precht LM, Lowe KA, Atwood M, Beatty JD, (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16: 362-368. PubMed: 20443786.
25. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E, (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48: 3342-3354. doi:10.1016/j.ejca.2012.05.023. PubMed: 22766518.
26. Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, et al. (2007) Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc 226: 244-255. doi:10.1111/j.1365-2818.2007.01772.x. PubMed: 17535263.
27. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF, (2006) Molecular classification of breast cancer: limitations and potential. Oncologist 11: 868-877. doi:10.1634/theoncologist.11-8-868. PubMed: 16951390.
28. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795. doi:10.1200/JCO.2009.25.6529. PubMed: 20404251.
29. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, et al. (2013) Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 24: 101-108. doi:10.1093/annonc/mds248. PubMed: 23002281.
30. Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA, (2007) 18F-Fluoroestradiol. Semin Nucl Med 37: 470-476. PubMed: 17920354.
31. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, et al. (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113: 509-517. doi:10.1007/s10549-008-9953-0. PubMed: 18327670.
32. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, et al. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24: 2793-9. PubMed: 16682724.
33. van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, et al. (2012) PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 53: 182-190. doi:10.2967/jnumed.111.092734. PubMed: 22241912.
34. Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, et al. (2011) Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med 52: 1541-1549. doi:10.2967/jnumed.111.091439. PubMed: 21903739.